In an October 28, 2011, Federal Register notice, the National Cancer Institute’s (NCI) Alliance for Nanotechnology in Cancer announced the initiation of “Translation of Nanotechnology in Cancer” (TONIC), a public private industry partnership intended to promote translational research and development opportunities of nanotechnology-based cancer solutions. The notice states that an immediate consequence of this effort

The August 2008 issue of The Lancet Oncology includes an article entitled “Special Report: Policy — Future Priorities for IARC Monographs.” According to the article, carbon-based nanomaterials and ultrafine particles are included on the list of substances recommended by the International Agency for Research on Cancer (IARC) Advisory Group as high priority for assessment. The article

The National Institute of Standards and Technology (NIST) will hold an October 8-9, 2008, workshop regarding enabling standards for nanomaterial characterization.  According to the workshop overview, there is an “urgent need” to elevate new protocols and practices for characterizing the physicochemical properties of nanomaterials, and their in vitro and in vivo properties with respect to

The International Agency for Research on Cancer (IARC) recently solicited nominations for substances for review in future IARC Monographs, which identify environmental factors that can increase the risk of human cancer. IARC states that it will select substances for review based on: (a) evidence of human exposure; and (b) evidence or suspicion of carcinogenicity. The 51 substances nominated include carbon nanotubes, which received three nominations:
Continue Reading